Persistent infection drives the development of CD8 + T cells specific for late lytic infection antigens in lymphocryptovirus-infected macaques and Epstein-Barr virus-infected humans

Journal of Virology

Volumn 85, Issue 23, 2011, Pages 12821-12824

  Orlova, Nina ^a   Wang, Fred ^a   Fogg, Mark H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EARLY ANTIGEN; LATE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN SPECIFICITY; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL SPECIFICITY; DISEASE DURATION; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNE EVASION; NONHUMAN; NOTE; PERSISTENT INFECTION; PRIORITY JOURNAL; RHESUS MONKEY;

ADULT; ANIMALS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNE EVASION; LYMPHOCRYPTOVIRUS; MACACA MULATTA; TUMOR VIRUS INFECTIONS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4; LYMPHOCRYPTOVIRUS; MACACA; MACACA MULATTA;

EID: 81255173563     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05742-11     Document Type: Note

References (20)

1. Apolloni, A., and T. B. Sculley. 1994. Detection of A-type and B-type Epstein-Barr virus in throat washings and lymphocytes. Virology 202:978-981.
2. + T cell responses in EBV infection. J. Immunol. 167:4450-4457.
3. Cho, Y. G., A. V. Gordadze, P. D. Ling, and F. Wang. 1999. Evolution of two types of rhesus lymphocryptovirus similar to type 1 and type 2 Epstein-Barr virus. J. Virol. 73:9206-9212.
4. Croft, N. P., et al. 2009. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog. 5:e1000490.
5. Fogg, M. H., D. Garry, A. Awad, F. Wang, and A. Kaur. 2006. The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques. J. Immunol. 176:3391-3401.
6. + T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue. J. Virol. 79:12681-12691.
7. + T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 106:3318-3323.
8. + T cells is critical for superinfection by cytomegalovirus. Science 328:102-106.
9. + T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J. Exp. Med. 204:1863-1873.
10. Horst, D., et al. 2009. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J. Immunol. 182:2313-2324.
11. + immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J. Exp. Med. 201:349-360.
12. Rabin, H., R. H. Neubauer, R. F. Hopkins III, and M. Nonoyama. 1978. Further characterization of a herpesvirus-positive orang-utan cell line and comparative aspects of in vitro transformation with lymphotropic old world primate herpesviruses. Int. J. Cancer 21:762-767.
13. Rivailler, P., H. Jiang, Y. G. Cho, C. Quink, and F. Wang. 2002. Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model. J. Virol. 76:421-426.
14. Rooney, C. M., et al. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13.
15. Sculley, T. B., A. Apolloni, L. Hurren, D. J. Moss, and D. A. Cooper. 1990. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J. Infect. Dis. 162:643-648.
16. Tierney, R. J., et al. 2006. Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J. Infect. Dis. 193:287-297.
17. van Gent, M., et al. 2011. EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection. J. Immunol. 186:1694-1702.
18. Yao, Q. Y., et al. 1996. Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals. J. Virol. 70:4884-4894.
19. Zuo, J., et al. 2009. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 5:e1000255.
20. + T cells through an additional host shutoff function. J. Virol. 82:2385-2393.